Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
During the Academy of Managed Care Pharmacy (AMCP) annual meeting, Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighed in on the factors he thinks will most impact market share among adalimumab biosimilars when they enter the US market in 2023
Transcript
With there being 7 FDA-approved adalimumab biosimilars and potentially more coming in the next year and a half, what factor do you think is going to be the most impactful on market share?
There's 7 that could be launched because they're approved currently, but there's actually 8, so we could get 8 original formulations in 2023. In 2023, we could get a couple 100-mg/mL approvals. So, I would say in 2023, the highest potential number we could get is around 10 launches.
And then the most impactful factors on their adoption: No. 1 is that about 2 or 3 weeks ago, there was a settlement agreement between Alvotech and AbbVie. And this had to do with the new formulation [100 mg/mL, high concentration]. It was very unclear, very cloudy on the future of biosimilars to the new formulation of Humira [reference adalimumab] coming to market and when that would take place. The settlement agreement kind of cleared that up; the skies got nice and blue. And we think that now we're going to get that 100-mg/mL launch in mid 2023. So, that's by far the most impactful thing because 80% of the utilization or more for Humira is in that new formulation.
So, that changes the view from a payer standpoint on how to add those products to the formulary. Citrate free is a is another issue that we'll mention that's impactful. One thing maybe people aren't thinking about is AbbVie's willingness to contract Humira cost down. So that will impact the adoption of biosimilar. How low are they willing to go? Interchangeability, the ever-elusive interchangeability, will also impact that.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.